Eli Lilly And Co (NYSE:LLY) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $5.55-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.58. The company issued revenue guidance of $24.3-24.5 billion, compared to the consensus revenue estimate of $24.41 billion.Eli Lilly And Co also updated its FY19 guidance to $5.90-6.00 EPS.
A number of analysts have issued reports on the company. Citigroup downgraded Eli Lilly And Co from a buy rating to a neutral rating and set a $113.00 price objective on the stock. in a research note on Sunday, December 2nd. Zacks Investment Research downgraded Eli Lilly And Co from a buy rating to a hold rating in a research note on Tuesday, December 4th. Guggenheim assumed coverage on Eli Lilly And Co in a research note on Monday, October 8th. They issued a buy rating on the stock. ValuEngine raised Eli Lilly And Co from a hold rating to a buy rating in a research note on Monday, October 8th. Finally, JPMorgan Chase & Co. set a $123.00 price objective on Eli Lilly And Co and gave the stock a buy rating in a research note on Friday, October 5th. Nine equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $110.82.
Shares of Eli Lilly And Co stock opened at $106.50 on Wednesday. The company has a market capitalization of $114.79 billion, a PE ratio of 24.88, a P/E/G ratio of 1.69 and a beta of 0.31. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. Eli Lilly And Co has a one year low of $73.69 and a one year high of $119.84.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $0.645 dividend. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.42%. Eli Lilly And Co’s payout ratio is 52.57%.
In other news, SVP Myles O’neill sold 25,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the transaction, the senior vice president now owns 26,562 shares in the company, valued at approximately $2,999,381.04. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the transaction, the insider now owns 3,148,647 shares of the company’s stock, valued at approximately $44,081,058. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,951,367 shares of company stock valued at $151,341,095. Company insiders own 0.11% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Eli Lilly And Co (LLY) Issues FY18 Earnings Guidance” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4027406/eli-lilly-and-co-lly-issues-fy18-earnings-guidance.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Yield Curve
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.